The role of extracorporeal life support in the management with severe idiopathic pulmonary artery hypertension undergoing lung transplantation: are those patients referred too late?
Lung transplantation (LTx)
extracorporeal life support (ECLS)
pulmonary artery hypertension
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
ppublish
Résumé
Idiopathic pulmonary artery hypertension (iPAH) is a relatively minor indication for lung transplantation (LTx) with comparatively poorer outcomes. Extracorporeal life support (ECLS) in various forms is increasingly being used in the management of this entity. However, the data and experience with this therapy remains limited. We evaluated the role of ECLS in the management of severe iPAH patients as a bridge to LTx as well as post LTx support. A retrospective analysis of iPAH patients that received LTx between January 2007 and May 2014 was performed. Early- and mid-term outcomes were analyzed for this patient cohort. Also, early and mid-term outcomes after LTx were compared to the control group of patients with other diagnoses using unadjusted analysis and 1:3 propensity score matching. Of 321 LTx performed during the study period in our centre 15 patients had iPAH as a cause of end-stage lung disease. Four iPAH (27%) patients were bridged to LTx utilizing ECLS in the form of veno-arterial ECMO and extra-corporeal CO ECLS is an essential tool in the armamentarium of any lung transplant program treating iPAH with a potential of bridge patients to transplantation and to overcome graft dysfunction after LTx. Despite utilization of ECLS in the management of iPAH, the outcomes in terms of primary graft failure and survival remain poor compared to patients with other diagnoses.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary artery hypertension (iPAH) is a relatively minor indication for lung transplantation (LTx) with comparatively poorer outcomes. Extracorporeal life support (ECLS) in various forms is increasingly being used in the management of this entity. However, the data and experience with this therapy remains limited. We evaluated the role of ECLS in the management of severe iPAH patients as a bridge to LTx as well as post LTx support.
METHODS
METHODS
A retrospective analysis of iPAH patients that received LTx between January 2007 and May 2014 was performed. Early- and mid-term outcomes were analyzed for this patient cohort. Also, early and mid-term outcomes after LTx were compared to the control group of patients with other diagnoses using unadjusted analysis and 1:3 propensity score matching.
RESULTS
RESULTS
Of 321 LTx performed during the study period in our centre 15 patients had iPAH as a cause of end-stage lung disease. Four iPAH (27%) patients were bridged to LTx utilizing ECLS in the form of veno-arterial ECMO and extra-corporeal CO
CONCLUSIONS
CONCLUSIONS
ECLS is an essential tool in the armamentarium of any lung transplant program treating iPAH with a potential of bridge patients to transplantation and to overcome graft dysfunction after LTx. Despite utilization of ECLS in the management of iPAH, the outcomes in terms of primary graft failure and survival remain poor compared to patients with other diagnoses.
Identifiants
pubmed: 31183172
doi: 10.21037/jtd.2019.04.58
pii: jtd-11-S6-S929
pmc: PMC6535489
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S929-S937Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Clin Chest Med. 2001 Sep;22(3):583-93
pubmed: 11590850
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
pubmed: 16456139
Eur Respir J. 2007 Jul;30(1):104-9
pubmed: 17360728
Ann Intern Med. 1991 Sep 1;115(5):343-9
pubmed: 1863023
Clin Transplant. 2009 Nov-Dec;23(6):819-30
pubmed: 19239481
Am J Respir Crit Care Med. 2009 Sep 1;180(5):468-74
pubmed: 19520906
Eur Respir J. 2009 Dec;34(6):1219-63
pubmed: 19749199
J Heart Lung Transplant. 2009 Oct;28(10):1031-49
pubmed: 19782285
J Thorac Cardiovasc Surg. 2009 Nov;138(5):1234-1238.e1
pubmed: 19837222
J Thorac Cardiovasc Surg. 2010 Mar;139(3):765-773.e1
pubmed: 19931096
Curr Opin Crit Care. 2010 Feb;16(1):53-61
pubmed: 20019609
Am J Transplant. 2010 Sep;10(9):2173-8
pubmed: 20636463
J Heart Lung Transplant. 2011 Sep;30(9):997-1002
pubmed: 21489818
Nat Rev Cardiol. 2011 Jul 19;8(9):526-38
pubmed: 21769113
Respir Care. 2011 Oct;56(10):1555-72
pubmed: 22008397
Am J Respir Crit Care Med. 2012 Apr 1;185(7):763-8
pubmed: 22268135
Eur Respir Rev. 2012 Sep 1;21(125):218-22
pubmed: 22941886
J Heart Lung Transplant. 2012 Oct;31(10):1073-86
pubmed: 22975097
Am J Respir Crit Care Med. 2013 Mar 1;187(5):527-34
pubmed: 23306540
Semin Respir Crit Care Med. 2013 Jun;34(3):281-7
pubmed: 23821503
Asian Cardiovasc Thorac Ann. 2013 Jun;21(3):326-30
pubmed: 24570500
Eur J Cardiothorac Surg. 2014 Dec;46(6):e82-8
pubmed: 25342851